Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!

Zumedha - Investments

Research · Analysis · Insights

Zumedha - Investments

Research · Analysis · Insights

  • Home
  • Home
Close

Search

Subscribe

Zumedha - Investments

Research · Analysis · Insights

Zumedha - Investments

Research · Analysis · Insights

  • Home
  • Home
Close

Search

Subscribe

Swiggy Limited — Investment Research Report March 2026

Zumedha Research Team By Zumedha Research Team
No Comments on Swiggy Limited — Investment Research Report March 2026
8 Min Read

Swiggy Limited — Investment Research Report NSE: SWIGGY  |  BSE: 544357  |  Consumer Internet Zumedha Equity Research As of 31 March 2026 CMP ₹260–269 52W High ₹474 52W Low ₹266 Mkt Cap ₹74,128 Cr 1Y Return –20.4% Consensus BUY…

Consumer ServicesQuick COmmerce
April 5, 2026

Zumedha Research Team By Zumedha Research Team
No Comments on
6 Min Read

GMR Airports Ltd — Investment Analysis Report Zumedha Equity Research | Indian Equity Analysis | Infrastructure · Aviation | 31 Mar 2026 NSE GMRAIRPORT CMP ₹88.50 ▼ 1.2% 52W H/L ₹110.36 / ₹67.75 Mkt Cap ~₹96,300 Cr Rating ACCUMULATE GMR Airport Equity…

AviationInfrastructure Sector
April 5, 2026

Gold in 2006 : Buying, Selling, ETFs &The Road Ahead

Zumedha Research Team By Zumedha Research Team
No Comments on Gold in 2006 : Buying, Selling, ETFs &The Road Ahead
8 Min Read

Gold Investment Analysis — March 2026 Investment Research ◆ Gold & Precious Metals ◆ 31 March 2026 GOLD (USD/oz) $4,567 GOLD (₹/10g 24K) ₹1,48,260 22K ₹/10g ₹1,35,900 SILVER ₹/kg ₹2,50,000 USD/INR ~86.5 Comprehensive Investment Report Gold: Buying,…

Metals
April 5, 2026

Suven Life Sciences Value Analysis March 2026

Zumedha Research Team By Zumedha Research Team
No Comments on Suven Life Sciences Value Analysis March 2026
7 Min Read

Suven Life Sciences — Investment Analysis Report Equity Research | NSE: SUVEN  ·  BSE: 530239  ·  Indian Pharmaceuticals / CNS Biotech March 2026 Deep Dive · Investment Analysis Report Suven Life SciencesLimited India’s only…

Bio ScienceBioTech Stocks
April 1, 2026

Wipro Ltd DCF Valuation Analysis March 2026

Zumedha Research Team By Zumedha Research Team
No Comments on Wipro Ltd DCF Valuation Analysis March 2026
7 Min Read

Wipro Ltd — Investment Research Report Equity Research | Information Technology | NSE: WIPRO  ·  BSE: 507685 March 31, 2026 CMP (NSE) ₹189 | 52-Week High ₹274.70 | 52-Week Low ₹187.00 | Market Cap ₹1,97,958 Cr | 1-Yr Return ▼ 29.4% Investment…

IT
April 1, 2026

YES Bank DCF Value Analysis March 2026

Zumedha Research Team By Zumedha Research Team
No Comments on YES Bank DCF Value Analysis March 2026
7 Min Read

YES Bank — Deep Analysis Report EQUITY RESEARCH ◆ NSE: YESBANK | BSE: 532648 | SECTOR: PRIVATE SECTOR BANKING | March 30, 2026 CMP₹18.50–19.50 | 52W H/L₹24.30 / ₹16.09 | MKTCAP~₹59,000 Cr | P/ABV (FY26E)~1.2x | Q3 FY26 PAT₹952 Cr (+55% YoY) | GROSS…

Banking & Finance
April 1, 2026

Exide Industries DCF Value Analysis March 2026

Zumedha Research Team By Zumedha Research Team
No Comments on Exide Industries DCF Value Analysis March 2026
7 Min Read

Exide Industries — Investment Research Report Equity Research NSE: EXIDEIND| BSE: 500086| Sector: Auto Components / Batteries| March 31, 2026 CMP ₹300.85 52W High ₹431.00 52W Low ₹295.50 Mkt Cap ₹25,572 Cr P/E (TTM) 31.7x 1Y Return −10.9% Div. Yield…

Auto ComponentsBattery Industries
April 1, 2026

Coal India Share Value Analysis March 2026

Zumedha Research Team By Zumedha Research Team
No Comments on Coal India Share Value Analysis March 2026
7 Min Read

Coal India — Investment Research Report Equity Research NSE · COALINDIA BSE · 533278 30 March 2026 Maharatna PSU In-Depth Investment Analysis Coal IndiaLimited India’s coal monopoly — dividend fortress or a sunset industry? BUY Target ₹530 Dividend…

Power & Energy
March 31, 2026

Indegene Ltd (INDGN) DCF Value Analysis March 2026

Zumedha Research Team By Zumedha Research Team
No Comments on Indegene Ltd (INDGN) DCF Value Analysis March 2026
6 Min Read

Indegene Ltd (INDGN) — Investment Research Report EQUITY RESEARCH  |  HEALTHCARE TECHNOLOGY  |  NSE: INDGN  |  BSE: 544172 March 2026  |  For Informational Purposes Only CMP ₹452 | 52W H ₹633 | 52W L ₹414 | Mkt Cap…

HealthcareTechnology
March 31, 2026

NALCO DCF Value Analysis March 2026

Zumedha Research Team By Zumedha Research Team
No Comments on NALCO DCF Value Analysis March 2026
9 Min Read

NALCO — Equity Research Report Equity Research NSE: NATIONALUM|BSE: 532234|Metals & Mining · Non-Ferrous|31 March 2026 CMP₹386 52W HIGH₹431.5 52W LOW₹137.75 Mkt Cap₹70,912 Cr P/E11.09x P/B3.44x EPS (FY25)₹28.68 Div Yield~3.7% ✦ BUY — Strong…

Metals
March 31, 2026
1 2 3 Next »

Recent Posts

  • Swiggy Limited — Investment Research Report March 2026
  • (no title)
  • Gold in 2006 : Buying, Selling, ETFs &The Road Ahead
  • Suven Life Sciences Value Analysis March 2026
  • Wipro Ltd DCF Valuation Analysis March 2026
Legal Disclaimer Investment Research & Information

Not Investment Advice. All content published on this website — including stock analyses, mutual fund reviews, DCF models, valuation estimates, buying zones, and commentary — is created for our own educational, internal research and informational purposes only. Nothing on this website constitutes financial, investment, legal, or tax advice, nor a solicitation or recommendation to buy, sell, or hold any security or financial instrument.

No Guarantees. It is advised clearly and categorically not o follow these analysis and information blindly for your equity investement purpose as Equity investments and mutual funds are subject to market risks. Past performance is not indicative of future results. All DCF models, fair value estimates, and scenario analyses are based on publicly available data and the author's independent assumptions and may prove materially incorrect. The author/s or owners of this website/portal do not are not liable in whatsoever manner for any positive or negative outcome from your own investment endeavorsYou may lose part or all of your invested capital.

Do Your Own Research. Readers are strongly advised to consult a SEBI-registered investment advisor and conduct their own due diligence before making any investment decision. The author may or may not hold positions in securities discussed on this website.

No Obligations. We, the author/ the publisher/ anybody associated with Zumedha.com does not guarantee the accuracy, adequacy or completeness of any information/data and is not responsible for any errors or omissions or for the results obtained from the use of such information/data. Zumedha.com or anyone involved with zumedha.com will not accept any liability for loss or damage as a result of reliance on the Estimates data. It does not subscribe or endorse any of the services and/or content offered by such third party.

Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
This website is not registered as an Investment Adviser under SEBI (Investment Advisers) Regulations, 2013. All views are personal and for informational purposes only.
© 2026 · All Rights Reserved · For Educational Use Only. RESEARCH · ANALYSIS · INSIGHTS